Euglycemic Diabetic Ketoacidosis, Recurrent Genital Abscess, and Proximal Renal Tubular Acidosis With Concurrent SGLT-2 Inhibitor: More Than an Association.
正常血糖性糖尿病酮酸中毒、反覆生殖器膿腫及近端腎小管酸中毒與同時使用 SGLT-2 抑制劑：不僅僅是關聯。
Cureus 2024-09-23
[Mechanism of Panax notoginseng saponins in treating diabetic kidney disease based on network pharmacology and experimental verification].
基於網絡藥理學和實驗驗證的Panax notoginseng皂苷治療糖尿病腎病的機制。
Zhongguo Zhong Yao Za Zhi 2024-09-22
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand.
在心衰竭的2型糖尿病患者中，將SGLT-2抑制劑添加至標準治療的成本效用及預算影響分析：利用來自泰國的國家數據庫見解。
Pharmacoecon Open 2024-09-22
Use of SGLT-2 Inhibitors in Adults (Age ≥ 65) with Type 2 Diabetes and Cardiovascular Disease is Lower in Alberta and Manitoba than in Ontario (2018-2020): A Cross-Sectional Study of Different Drug Funding Policies.
65 歲以上成人（年齡 ≥ 65）中，使用 SGLT-2 抑制劑的情況在阿爾伯塔省和曼尼托巴省低於安大略省（2018-2020）：不同藥物資助政策的橫斷面研究。
Can J Diabetes 2024-09-20
[Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation].
「高選擇性鈉-葡萄糖共轉運蛋白2抑制劑 empagliflozin 在慢性腦循環障礙條件下的腦保護作用」
Probl Endokrinol (Mosk) 2024-09-20
Empagliflozin Dampens Doxorubicin-Induced Chemobrain in Rats: The Possible Involvement of Oxidative Stress and PI3K/Akt/mTOR/NF-κB/TNF-α Signaling Pathways.
Empagliflozin 減弱多柔比星誘導的化療腦症在大鼠中的影響：氧化壓力及 PI3K/Akt/mTOR/NF-κB/TNF-α 信號通路的可能參與。
Mol Neurobiol 2024-09-20
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.
2型糖尿病中的心血管表現：CANVAS計畫和CREDENCE試驗的潛在類別分析。
Diabetes Obes Metab 2024-09-20